Natco Pharma’s partner Mylan settles Ozempic patent dispute
The terms of the agreement remain confidential.
Natco Pharma announced that its partner, Mylan Pharmaceuticals, reached a settlement with Novo Nordisk in the ongoing U.S. patent litigation related to generic Ozempic (Semaglutide).
The terms of the agreement remain confidential.
Natco and Mylan have been collaborating on the development of generic Ozempic products, and Stelis is Natco's manufacturing partner.
[Read more: Diabetes market faces disruption]
Ozempic, a glucagon-like peptide-1 receptor agonist is used to manage Type 2 diabetes and promote weight loss.